| Potential Diagnosis And Treatment For LAM Lung Disease
ScienceDaily (Jan. 15, 2008) New studies are providing clues into the treatment and diagnosis of LAM, or lymphangioleiomyomatosis, a progressive and deadly lung disease that affects women in their childbearing years. There currently are no treatments for LAM and scientists estimate as many as 250,000 women may be going misdiagnosed or undiagnosed. .
amfAR Appoints New Leadership as AIDS Research Organization Extends ...
Food and Drug Administration hearings on AIDS-related drug treatments. He has published in numerous journals including The Lancet, Journal of Clinical Epidemiology, Journal of AIDS (JAIDS), Journal of Infectious Diseases, and The AIDS Reader. "amfAR's 25 years of experience fighting AIDS obligates us to do all we can in our efforts to end this pandemic," Mr. Frost said. "And while the needs are great, amfAR is well positioned to continue to make major contributions to HIV research, prevention, treatment, and advocacy in the coming years. I'm honored by this appointment and I look forward to working with my colleagues at amfAR to take on the complex challenges that lie ahead." Since becoming chairman of amfAR's Campaign for AIDS Research in 1995, Sharon Stone has traveled nationally and internationally on the Foundation's behalf.
First of two reports: FDA's Fast Track designation more help to ...
A decade ago, the Food and Drug Administration introduced a Fast Track designation for drugs in development that was intended to speed the availability of medical treatments for serious diseases. However, a seven-month investigation by The Plain Dealer shows that this government blessing has not increased the number of drugs approved or moved them to market faster. Instead, Fast Track has given the drug industry, which came up with the idea for the designation and lobbied for its passage, a device that promises a lot but delivers little to anyone but investors. The news of Fast Track designation creates a boon for day traders, hedge funds and others looking to make quick money off biotech stocks. Some biotech executives also have tried to turn the FDA's Fast Track designation into personal gain.
|
